Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554795 | 0.82 | HRH3 (0.40) | KDM4ETDP1ALDH1A1NCF1PRMT6 | |
| SCHEMBL1681215 | 0.81 | HRH3 (0.43) | KDM4ETDP1ALDH1A1HRH4 | |
| SCHEMBL12468741 | 0.81 | HRH3 (0.43) | KDM4ETDP1ALDH1A1HRH4 | |
| SCHEMBL5095279 | 0.78 | CYP2C9 (0.46) | LMNAKDM4ETDP1ALDH1A1NCF1 | |
| SCHEMBL15323562 | 0.75 | LTA4H (0.36) | KDM4EALDH1A1 | |
| SCHEMBL8050325 | 0.72 | MC4R (0.44) | MC4RLMNACHKAKDM4ETDP1 | |
| SCHEMBL3838774 | 0.71 | HRH3 (0.41) | NCF1HRH4 | |
| SCHEMBL4496754 | 0.71 | LTA4H (0.44) | KDM4EALDH1A1 | |
| SCHEMBL6224318 | 0.69 | MEN1 (0.52) | PRMT6 | |
| SCHEMBL468785 | 0.69 | ADRA2C (0.34) | KDM4EALDH1A1MAPTHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074095-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2009-07-01 | — | — | EP | claimed |
| WO-2008059551-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2008-05-22 | — | — | WO | claimed |
| EP-2838534-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | The Board of Trustees of The Leland Stanford Junior University (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013155338-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-10-17 | — | — | WO | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-2376494-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2074095-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2009-07-01 | — | — | EP | disclosed |
| EP-1987060-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007089716-A2 | USE OF AMINOPYRIMIDINE COMPOUNDS IN THE TREATMENT OF IMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1633317-A2 | SYNTHETIC CHEMOKINE RECEPTOR LIGANDS AND METHODS OF USE THEREOF | Intermune, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110478-A2 | COMBINATION THERAPY FOR TREATING FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005016241-A2 | SYNTHETIC CHEMOKINE RECEPTOR LIGANDS AND METHODS OF USE THEREOF | INTERMUNE, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| EP-0901488-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043277-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-20 | — | — | WO | disclosed |